Key Highlights

  • FDA approved Pasatru (garetosmab-grts) on Aug 19, 2026 for adults with FOP; the Phase 3 OPTIMA trial showed a 90% cut in new bone lesions at 10 mg/kg.
  • Pasatru carries an average annual list price of about $1.4 million, with Ipsen's Sohonos as the main competitor.
  • Q2 2026 Revenue rose 17% to $4.3 billion as Dupixent sales hit $6.0 billion, while total US Eylea sales fell 12%.
  • Regeneron repurchased $2.0 billion of stock in the first half of 2026 and declared a quarterly Dividend of $0.94 per share, while Libtayo global sales rose 30% to $489 million.

The Food and Drug Administration's Aug 19 approval of Pasatru (garetosmab-grts) gives Regeneron Pharmaceuticals (NASDAQ:REGN) a new rare-disease product. Its effect on the company's roughly $4 billion-a-quarter revenue base will be modest, but it strengthens the company's position in ultra-rare disorders. Pasatru is approved for adults with fibrodysplasia ossificans progressiva (FOP). The genetic disorder gradually turns muscle, tendons and ligaments into bone, and the FDA called Pasatru the second drug approved for the condition.

For shareholders, the approval matters in three ways. It adds a high-priced orphan medicine with strong efficacy data. It puts Regeneron in direct competition with Ipsen's Sohonos, the first FOP therapy, which has sold poorly. It also validates an antibody program that had once been paused over safety concerns. However, the patient population is very small. Regeneron puts it at about 900 people worldwide, with a prevalence of roughly 1 in 1 million. That means Pasatru is unlikely to change the company's Earnings picture, which still depends mainly on Dupixent and the Eylea franchise.

What the FDA Cleared on Aug 19

According to Regeneron's Aug 19 press release, Pasatru is indicated to reduce new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with FOP. It is given by intravenous infusion at 10 mg/kg once every four weeks, and the dose can be lowered to 3 mg/kg if the higher dose isn't tolerated. The company said the drug can be administered in home infusion settings.

The approval rested on the Phase 3 OPTIMA trial. According to the company, the 10 mg/kg dose cut new HO lesions by 90% compared with placebo (2 lesions against 19) and reduced clinician-assessed flare-ups by 88%. At 3 mg/kg, new lesions fell by 94%, but flare-ups fell by only 15%. The FDA said the trial enrolled 63 participants. The agency's announcement said the drug received Breakthrough Therapy, Fast Track, Orphan Drug and Priority Review designations.

The label carries warnings. The FDA flagged a risk of fetal harm, and patients must use effective contraception during treatment and for six months after the last dose. It also flagged skin and soft-tissue infections requiring medical intervention and nosebleeds requiring medical attention. The most common adverse reactions listed were nosebleeds, increased hair growth, abscess and acne. Regeneron said a regulatory submission is under review by the European Medicines Agency.

Pricing and the Commercial Opportunity

Pasatru carries an average annual list price of about $1.4 million per patient. Depending on weight and dose, the price ranges from roughly $693,000 to $2.1 million. With a global population of about 900 people, and only a fraction of them diagnosed, treated adults in markets where the drug is available, even strong uptake would produce revenue that is small relative to Regeneron's overall sales.

The competitive picture favors Regeneron. Ipsen's Sohonos (palovarotene) was approved in 2023. Sohonos generated about $24 million in sales in the first half of 2026, unchanged from a year earlier, and Ipsen recorded a €279 million Impairment on the drug in 2024. FDA reviewers had previously raised concerns about inflammatory flare-ups with Sohonos. There's no head-to-head trial, so any direct comparison of the two drugs should be treated with caution.

Patient advocates welcomed the decision. Michelle Davis, executive director of the International FOP Association, called the approval "monumental for our community."

Why the Program's History Matters

Garetosmab's path to approval was not straightforward. An earlier Phase 2 study was paused after several participants died. Regeneron investigated and concluded the drug was likely not responsible, and it then moved the program into late-stage testing. The approval therefore closes a program that faced real safety questions along the way, and post-marketing safety data will be closely watched.

The approval also shows the reach of Regeneron's VelocImmune antibody platform into genetic diseases. Garetosmab targets activin A, a protein implicated in the abnormal bone formation that drives FOP.

Dupixent and Eylea Still Drive the Numbers

Regeneron's financial profile is shaped far more by its large franchises. In its Jul 30 second-quarter release, the company reported total revenue of $4.3 billion, up 17% from a year earlier. GAAP EPS was $12.23, non-GAAP EPS was $14.29, and Net Income was $1.297 billion.

Dupixent, which Regeneron develops and commercializes with Sanofi (NASDAQ:SNY), posted global sales of $6.0 billion, which the company called a new all-time high, up 38%. Collaboration revenue from Sanofi rose 51% to $2.174 billion, and Regeneron said it had fully repaid its Sanofi Development Balance, which it expects to enhance its future profit share. Libtayo global sales rose 30% to $489 million.

The ophthalmology Business is the weaker spot. US sales of Eylea HD climbed 52% to $596 million, but total US Eylea sales, including the original formulation, fell 12% to $1.008 billion. The company attributed the decline to competitive pressures. Regeneron repurchased $2.0 billion of stock in the first half of 2026 and declared a quarterly dividend of $0.94 per share.

Risks Investors Are Weighing

The main risks for the stock lie beyond Pasatru. Eylea faces continued pressure from Biosimilars and from competing retinal therapies. Dupixent's growth, while strong, concentrates a large share of profit in a single product shared with a partner. Drug-pricing policy in the United States, including Medicare negotiation and potential tariff-related measures, adds uncertainty across the sector.

For Pasatru itself, the main risks are a slow commercial launch in a tiny, geographically scattered population, reimbursement hurdles given the seven-figure price, the label's safety warnings and the approval being limited to adults. European approval is still pending.

The Next Regulatory Checkpoints

Near-term catalysts include the FDA's decision on cemdisiran, Regeneron's C5-targeting RNAi therapy for generalized myasthenia gravis. The company said in its Jul 30 release that the drug has priority review with a target action date in November 2026. The company's third-quarter results, likely in late October or early November although the date had not been announced at the time of writing, should give an early view of Pasatru's launch, Dupixent momentum and Eylea HD's share gains.

Investors will also track the European Medicines Agency's review of garetosmab, any data on use in younger patients, and competitive responses from Ipsen. Pasatru won't swing Regeneron's earnings on its own. It does add to the company's rare-disease portfolio and shows that its antibody research engine can still deliver approvals in hard-to-treat conditions.